ADC Therapeutics Files S-4 for Switzerland-to-Delaware Redomiciliation, Shareholder Vote Required
ADCT sits 99% above its 52-week low of $0.78.
Summary
ADC Therapeutics filed an S-4 proxy/prospectus for a proposed move of its legal domicile from Switzerland to Delaware, with a 1-for-1 share conversion and no change in share count. Shareholders must approve the redomiciliation, new charter and bylaws, and a discharge of directors; the deal lapses if not closed by June 30, 2027.
Key Events · Corporate Governance and Compliance · ADCT
-
Redomiciliation to Delaware Proposed
The board unanimously approved moving incorporation from Switzerland to Delaware under PILA Article 163 and DGCL Section 388, continuing as ADC Therapeutics, Inc. with no liquidation or new legal entity.
-
One-for-One Share Conversion
Each Swiss common share (CHF 0.08 par) automatically becomes one share of Delaware common stock ($0.10 par); the filing states the transaction will not dilute economic interest and outstanding share count is unchanged.
-
Authorized Capital Set at 394M Common
The new charter authorizes 394,000,000 common shares and 3,000,000 preferred shares, with the board able to issue preferred and increase authorized common without a separate class vote.
-
Two-Thirds Vote Needed at EGM
Redomiciliation and charter proposals require two-thirds of votes represented plus a majority of par value represented; the discharge proposal needs a simple majority. Meeting date and record date are blank in this preliminary filing.
Analysis · ADCT · Life Sciences
ADC Therapeutics wants to reincorporate from Switzerland to Delaware, and this S-4 is the proxy/prospectus that puts the move to a shareholder vote. The share count does not change — each Swiss share becomes one Delaware share — so this is not a dilution event. What does change is the rulebook: a classified board, no ability for stockholders to call special meetings or act by written consent, 66 2/3% supermajority requirements, and Section 203 takeover protections. Management's stated rationale centers on cost savings from ending duplicate Swiss and U.S. reporting, a clearer U.S. identity for investors and partners, and more flexibility to issue shares for capital raises — meaningful for a company that has repeatedly needed to raise cash. The deal lapses if not completed by June 30, 2027, and it still needs Swiss tax rulings, a Lex Koller ruling, creditor confirmation, SEC effectiveness and NYSE listing approval. Watch the special meeting date, which is left blank in this preliminary filing.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADCT was trading at $1.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $197.9M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.